Dr Reddy's Enters Royalty-Free Agreement With Gilead For Annual Lenacapavir HIV Prevention

Market snapshot: Dr. Reddy's Laboratories has signed a royalty-free, non-exclusive voluntary licensing agreement with Gilead Sciences for its investigational once-yearly lenacapavir formulation. This strategic partnership expands their collaboration to support manufacturing readiness, technology transfer, and future supply planning for HIV pre-exposure prophylaxis (PrEP) across 120 high-incidence, low- and lower-middle-income countries, including India.

Data Snapshot

• The voluntary licensing agreement spans 120 high-incidence, low- and lower-middle-income countries, including India.
• This pact expands on a previous voluntary licensing agreement signed with Gilead in October 2024 for twice-yearly lenacapavir.
• Dr. Reddy's reported a consolidated revenue of ₹8,070.5 crore in Q1 FY27, a 5.55% year-on-year decline from ₹8,545.2 crore.
• The company's consolidated net profit dropped 68.7% year-on-year to ₹443.5 crore during Q1 FY27, impacted by inventory write-offs.

What's Changed

• The collaboration moves from twice-yearly injections (brokered in October 2024) to once-yearly investigational formulations to ease long-term adherence.
• Financial momentum remains muted near-term as Q1 FY27 revenues dropped 5.55% YoY due to generic lenalidomide sales erosion and a ₹240 crore provision for semaglutide API issues.

Key Takeaways

• Dr. Reddy's has signed a non-exclusive, royalty-free licensing agreement for investigational once-yearly lenacapavir with Gilead Sciences.
• The agreement enables early technology transfer, manufacturing readiness, and supply planning across 120 low- and middle-income countries.
• Once-yearly lenacapavir is an intramuscular formulation currently in Phase 3 trials under the PURPOSE 365 study.
• The agreement expands Dr. Reddy's public health portfolio, emphasizing global equity in accessing advanced infectious disease therapies.

SAHI Perspective

This expanded licensing pact with Gilead represents a strategic positioning of Dr. Reddy's sterile injectables manufacturing capability. While royalty-free agreements do not yield immediate blockbuster commercial revenue, securing early-stage access during Phase 3 clinical development ensures Dr. Reddy's can rapidly supply high-incidence markets upon regulatory approval. This long-term pipeline reinforcement is crucial as the company navigates temporary margins pressure and base generics erosion in developed markets.

Market Implications

The development is long-term positive for the stock, confirming Dr. Reddy's as a primary global partner for complex anti-infectives. However, near-term stock triggers remain bound to the operational resolution of semaglutide API issues and biosimilar approvals.

Trading Signals

Market Bias: Neutral

The licensing deal reinforces Dr. Reddy's long-term pipeline across emerging markets, but carries no immediate impact on earnings. Near-term margins remain pressured by a ₹240 crore semaglutide API provision and a 68.7% YoY drop in Q1 FY27 net profit to ₹443.5 crore.

Overweight: Healthcare, Pharmaceuticals

Trigger Factors:

• Results of the ongoing Phase 3 PURPOSE 365 clinical trial for once-yearly lenacapavir.
• Commercial resumption of semaglutide pens, estimated by management for November 2026.
• Regulatory clearance milestones for key biosimilars, such as the Abatacept BLA goal date in mid-December 2026.

Time Horizon: Medium-term (3-12 months)

Industry Context

Long-acting injectables represent a paradigm shift in global HIV prevention and treatment, significantly improving patient adherence over daily oral pills. International efforts led by organizations like Unitaid have driven generic affordability in resource-limited countries. For instance, Dr. Reddy's previously committed to supplying twice-yearly generic lenacapavir at an affordable price of approximately $40 per year in low- and middle-income nations, contrasting with the innovator's branded price of around $28,000 per year in developed markets.

Key Risks to Watch

• Clinical and regulatory failure if the Phase 3 PURPOSE 365 trials do not establish safety and efficacy for the once-yearly formulation.
• Delays in technology transfer or local regulatory approvals within target territories.
• Persistent quality-compliance risks at active pharmaceutical ingredient (API) facilities, which previously impacted semaglutide supplies.

Recent Developments

In August 2026, the CDSCO Subject Expert Committee recommended clinical trial and bioequivalence waivers for Dr. Reddy's generic twice-yearly lenacapavir, facilitating rapid manufacturing. Earlier in July 2026, Dr. Reddy's faced a semaglutide API quality setback, forcing a ₹240 crore provision that severely impacted Q1 FY27 margins. Additionally, the company terminated its promotion and distribution agreement with Novartis India Limited for select brands effective September 30, 2026.

Closing Insight

While Dr. Reddy's near-term operational margins face transient pressures from API quality disruptions, its expanding alliances with innovators like Gilead highlight its robust engineering capabilities in complex generic injectables, securing its role in the global public health supply chain.

High Performance Trading with SAHI.